Dietary	O
Zinc	O
Is	O
a	O
Key	O
Environmental	O
Modifier	O
in	O
the	O
Progression	O
of	O
IgA	B-DS
Nephropathy	I-DS

Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
YT	O
YS	O
M	O
.	O

Maiguma	O
HS	O
.	O

Performed	O
the	O
experiments	O
:	O
M	O
.	O

Maiguma	O
YS	O
.	O

Analyzed	O
the	O
data	O
:	O
M	O
.	O

Maiguma	O
YS	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
M	O
.	O

Maiguma	O
YS	O
M	O
.	O

Muto	O
KO	O
MI	O
.	O

Wrote	O
the	O
paper	O
:	O
M	O
.	O

Maiguma	O
YS	O
.	O

IgA	B-DS
nephropathy	I-DS
(	O
IgAN	B-DS
)	O
shows	O
diverse	O
epidemiological	O
characteristics	O
,	O
resulting	O
from	O
both	O
genetic	O
and	O
acquired	O
(	O
e	O
.	O
g	O
.,	O
environmental	O
)	O
causes	O
.	O

Environmental	O
factors	O
,	O
such	O
as	O
diet	O
or	O
exposure	O
to	O
exogenous	O
antigens	O
,	O
may	O
prescribe	O
the	O
progression	O
or	O
prognosis	O
of	O
IgAN	B-DS
.	O

It	O
remains	O
unclear	O
as	O
to	O
how	O
diet	O
and	O
infection	B-DS
influence	O
susceptibility	O
to	O
IgAN	B-DS
.	O

A	O
relationship	O
,	O
such	O
as	O
Toll	B-GP
-	I-GP
like	I-GP
receptors	I-GP
(	O
TLRs	B-GP
),	O
especially	O
TLR9	B-GP
and	O
TLR4	B-GP
,	O
was	O
demonstrated	O
between	O
IgAN	B-DS
and	O
pathogen	O
-	O
recognition	O
molecules	O
.	O

Recently	O
,	O
zinc	O
(	O
Zn	O
)	O
was	O
discovered	O
to	O
be	O
involved	O
in	O
various	O
immune	B-DS
-	I-DS
related	I-DS
diseases	I-DS
,	O
affecting	O
B	O
,	O
T	O
,	O
and	O
dendritic	O
cells	O
(	O
DCs	O
).	O

This	O
study	O
investigates	O
the	O
relationship	O
between	O
dietary	O
Zn	O
and	O
IgAN	B-DS
development	O
in	O
IgAN	B-DS
-	O
prone	O
mice	B-OG
.	O

Seven	O
-	O
week	O
-	O
old	O
IgAN	B-DS
-	O
prone	O
mice	B-OG
were	O
divided	O
into	O
low	O
,	O
normal	O
,	O
and	O
high	O
Zn	O
diet	O
groups	O
.	O

To	O
assess	O
exogenous	O
pathogen	O
-	O
mediated	O
immune	O
responses	O
,	O
lipopolysaccharide	O
(	O
LPS	O
)	O
was	O
nasally	O
administered	O
.	O

The	O
activity	O
of	O
IgAN	B-DS
was	O
biochemically	O
and	O
pathologically	O
evaluated	O
during	O
the	O
disease	O
course	O
.	O

We	O
also	O
examined	O
in	O
vitro	O
IgA	B-GP
production	O
in	O
spleen	O
cells	O
or	O
in	O
combinations	O
of	O
cocultured	O
B	O
,	O
T	O
,	O
and	O
DCs	O
under	O
various	O
Zn	O
conditions	O
with	O
or	O
without	O
LPS	O
.	O

Dietary	O
conditioning	O
with	O
Zn	O
affected	O
serum	O
immunoglobulins	B-GP
and	O
urinary	O
albumin	B-GP
levels	O
,	O
and	O
mesangial	O
deposition	O
of	O
IgA	B-GP
and	O
IgG	B-GP
.	O

Zn	B-DS
deficiency	I-DS
is	O
associated	O
with	O
IgAN	B-DS
progression	O
through	O
the	O
activation	O
of	O
the	O
TLR4	B-GP
/	O
TIR	B-GP
-	I-GP
domain	I-GP
-	I-GP
containing	I-GP
adapter	I-GP
-	I-GP
inducing	I-GP
interferon	I-GP
-	I-GP
β	I-GP
(	O
TRIF	B-GP
),	O
but	O
not	O
the	O
TLR9	B-GP
,	O
in	O
DCs	O
.	O

Zn	O
supplementation	O
prevented	O
disease	O
aggravation	O
.	O

Our	O
findings	O
indicate	O
that	O
immune	O
conditioning	O
with	O
dietary	O
Zn	O
alters	O
nephritogenic	O
IgA	B-GP
production	O
after	O
mucosal	B-DS
infection	I-DS
.	O

Introduction	O

First	O
described	O
by	O
Berger	O
et	O
al	O
.	O
in	O
1968	O
[	O
1	O
],	O
IgA	B-DS
nephropathy	I-DS
(	O
IgAN	B-DS
)	O
is	O
the	O
most	O
common	O
primary	O
chronic	B-DS
glomerulonephritis	I-DS
worldwide	O
.	O

Many	O
factors	O
,	O
including	O
mucosal	B-DS
infection	I-DS
[	O
2	O
],	O
[	O
3	O
],	O
genetic	O
predisposition	O
[	O
4	O
],	O
diet	O
[	O
5	O
],	O
and	O
hygiene	O
[	O
6	O
],	O
have	O
been	O
implicated	O
in	O
IgAN	B-DS
progression	O
.	O

Johnson	O
et	O
al	O
.	O
[	O
7	O
]	O
suggested	O
that	O
environmental	O
factors	O
,	O
such	O
as	O
exposure	O
to	O
antigens	O
,	O
affect	O
the	O
immune	O
system	O
and	O
explain	O
the	O
difference	O
in	O
IgAN	B-DS
prevalence	O
between	O
developing	O
and	O
industrial	O
countries	O
.	O

However	O
,	O
despite	O
long	O
-	O
term	O
research	O
,	O
the	O
precise	O
mechanism	O
by	O
which	O
environmental	O
factors	O
affect	O
IgAN	B-DS
severity	O
is	O
poorly	O
understood	O
.	O

The	O
pathological	O
impact	O
of	O
mucosal	B-DS
infection	I-DS
in	O
IgAN	B-DS
has	O
been	O
established	O
,	O
as	O
the	O
disease	O
is	O
frequently	O
exacerbated	O
by	O
upper	O
respiratory	O
or	O
gastrointestinal	B-DS
infections	I-DS
.	O

A	O
series	O
of	O
studies	O
are	O
underway	O
focusing	O
on	O
Toll	B-GP
-	I-GP
like	I-GP
receptors	I-GP
(	O
TLRs	B-GP
),	O
which	O
are	O
evolutionarily	O
conserved	O
regulators	O
of	O
the	O
innate	O
immune	O
response	O
.	O

TLR	B-GP
activation	O
may	O
represent	O
the	O
final	O
common	O
pathway	O
for	O
exogenous	O
antigens	O
,	O
which	O
have	O
a	O
negative	O
effect	O
on	O
the	O
mucosa	O
of	O
patients	O
with	O
IgAN	B-DS
.	O

We	O
have	O
reported	O
that	O
IgAN	B-DS
severity	O
correlates	O
with	O
splenic	O
TLR9	B-GP
expression	O
in	O
IgAN	B-DS
-	O
prone	O
mice	B-OG
[	O
8	O
].	O

In	O
addition	O
,	O
nasal	O
challenge	O
with	O
CpG	O
DNA	O
(	O
a	O
ligand	O
of	O
TLR9	B-GP
)	O
exacerbated	O
glomerular	O
damage	O
and	O
was	O
accompanied	O
by	O
increases	O
in	O
serum	O
IgA	B-GP
concentration	O
and	O
mesangial	O
IgA	B-GP
deposition	O
in	O
these	O
mice	B-OG
.	O

This	O
suggested	O
that	O
mucosal	O
stimulation	O
of	O
TLR	B-GP
may	O
be	O
linked	O
,	O
in	O
part	O
,	O
to	O
production	O
of	O
nephritogenic	O
IgA	B-GP
.	O

In	O
patients	O
with	O
IgAN	B-DS
,	O
the	O
expression	O
of	O
tonsillar	O
TLR9	B-GP
and	O
TLR9	B-GP
single	O
nucleotide	O
polymorphisms	O
was	O
correlated	O
with	O
the	O
efficacy	O
of	O
tonsillectomy	O
and	O
steroid	O
pulse	O
therapy	O
[	O
9	O
].	O

Coppo	O
et	O
al	O
.	O
[	O
10	O
]	O
reported	O
a	O
significant	O
correlation	O
between	O
TLR4	B-GP
expression	O
on	O
circulating	O
mononuclear	O
(	O
CD14	B-GP
+)	O
cells	O
and	O
the	O
levels	O
of	O
proteinuria	O
and	O
the	O
phases	O
of	O
clinical	O
activity	O
in	O
patients	O
with	O
IgAN	B-DS
.	O

Accordingly	O
,	O
TLR	B-GP
-	O
mediated	O
innate	O
immunity	O
may	O
be	O
significantly	O
involved	O
in	O
IgAN	B-DS
progression	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
prevalence	O
of	O
IgAN	B-DS
markedly	O
differs	O
depending	O
on	O
geographic	O
location	O
,	O
suggesting	O
the	O
importance	O
of	O
diet	O
and	O
socioeconomic	O
status	O
.	O

Donadio	O
et	O
al	O
.	O
[	O
11	O
]	O
proposed	O
that	O
dietary	O
supplementation	O
with	O
fish	B-OG
oils	O
could	O
benefit	O
patients	O
with	O
immune	B-DS
-	I-DS
related	I-DS
renal	I-DS
diseases	I-DS
,	O
including	O
IgAN	B-DS
,	O
lupus	B-DS
nephritis	I-DS
,	O
and	O
cyclosporine	O
-	O
induced	O
nephrotoxicity	O
.	O

Coppo	O
et	O
al	O
.	O
[	O
5	O
]	O
reported	O
the	O
influence	O
of	O
dietary	O
gluten	B-GP
on	O
primary	O
IgAN	B-DS
.	O

However	O
,	O
the	O
alimentary	O
effects	O
on	O
IgAN	B-DS
progression	O
remain	O
unclear	O
.	O

An	O
alimentary	O
zinc	O
(	O
Zn	O
)	O
plays	O
an	O
important	O
role	O
in	O
the	O
functioning	O
of	O
the	O
immune	O
system	O
[	O
12	O
].	O

Zn	O
is	O
a	O
non	O
-	O
redox	O
active	O
ion	O
essential	O
for	O
cell	O
growth	O
,	O
development	O
,	O
and	O
differentiation	O
.	O

In	O
addition	O
to	O
its	O
involvement	O
with	O
liver	B-DS
disease	I-DS
[	O
13	O
],	O
growth	O
retardation	O
,	O
and	O
cognitive	B-DS
impairment	I-DS
,	O
a	O
Zn	B-DS
deficiency	I-DS
has	O
many	O
other	O
negative	O
effects	O
[	O
14	O
],	O
[	O
15	O
].	O

Emerging	O
data	O
[	O
16	O
]–[	O
18	O
]	O
revealed	O
that	O
Zn	B-DS
deficiency	I-DS
in	O
humans	B-OG
was	O
correlated	O
with	O
an	O
increased	O
susceptibility	O
to	O
bacterial	O
and	O
/	O
or	O
viral	B-DS
infections	I-DS
,	O
suggesting	O
that	O
Zn	O
is	O
the	O
one	O
of	O
the	O
most	O
important	O
alimentary	O
factors	O
for	O
immune	O
responses	O
.	O

Indeed	O
,	O
patients	O
with	O
Zn	B-DS
deficiency	I-DS
show	O
defective	O
cellular	O
immunity	O
,	O
lymphopenia	B-DS
,	O
and	O
abnormalities	O
in	O
hematopoietic	O
cells	O
,	O
including	O
T	O
cells	O
[	O
19	O
],	O
natural	O
killer	O
cells	O
[	O
20	O
],	O
and	O
monocytes	O
[	O
21	O
].	O

Stimulation	O
with	O
the	O
TLR4	B-GP
agonist	O
LPS	O
altered	O
the	O
expression	O
of	O
Zn	B-GP
transporters	I-GP
in	O
the	O
dendritic	O
cells	O
(	O
DCs	O
),	O
thereby	O
decreasing	O
free	O
intracellular	O
Zn	O
levels	O
.	O

A	O
Zn	O
chelator	O
mimicked	O
the	O
effects	O
of	O
LPS	O
,	O
whereas	O
Zn	O
supplementation	O
or	O
overexpression	O
of	O
the	O
gene	O
encoding	O
Zip6	B-GP
,	O
a	O
Zn	B-GP
transporter	I-GP
whose	O
expression	O
is	O
reduced	O
by	O
LPS	O
,	O
inhibited	O
LPS	O
-	O
induced	O
upregulation	O
of	O
the	O
Class	B-GP
II	I-GP
major	I-GP
histocompatibility	I-GP
complex	I-GP
and	O
costimulatory	B-GP
molecules	I-GP
[	O
22	O
].	O

These	O
results	O
suggest	O
a	O
functional	O
linkage	O
between	O
TLR	B-GP
signaling	O
and	O
Zn	O
homeostasis	O
in	O
DCs	O
.	O

Ultimately	O
,	O
Zn	B-DS
deficiency	I-DS
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
immune	B-DS
diseases	I-DS
via	O
inappropriate	O
immunological	O
responses	O
.	O

In	O
fact	O
,	O
Zn	B-DS
deficiency	I-DS
is	O
often	O
observed	O
in	O
patients	O
with	O
autoimmune	B-DS
diseases	I-DS
[	O
16	O
].	O

Accordingly	O
,	O
we	O
hypothesized	O
that	O
dietary	O
Zn	O
levels	O
are	O
associated	O
with	O
susceptibility	O
to	O
IgAN	B-DS
via	O
the	O
modulation	O
of	O
the	O
innate	O
immune	O
response	O
in	O
the	O
mucosa	O
,	O
involving	O
nephritogenic	O
IgA	B-GP
production	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
assessed	O
this	O
hypothesis	O
in	O
IgAN	B-DS
-	O
prone	O
mice	B-OG
.	O

Materials	O
and	O
Methods	O

Mice	B-OG

The	O
“	O
grouped	O
ddY	O
”	O
(	O
gddY	O
)	O
mice	B-OG
were	O
established	O
by	O
selective	O
mating	O
of	O
early	O
-	O
onset	O
ddY	O
mice	B-OG
for	O
more	O
than	O
20	O
generations	O
.	O

This	O
resulted	O
in	O
a	O
100	O
%	O
incidence	O
of	O
severe	O
disease	O
at	O
a	O
young	O
age	O
[	O
8	O
],	O
[	O
23	O
]–[	O
25	O
].	O

The	O
mice	B-OG
were	O
maintained	O
in	O
an	O
SPF	O
room	O
at	O
the	O
animal	O
facility	O
of	O
Juntendo	O
University	O
,	O
Tokyo	O
,	O
Japan	O
.	O

The	O
experimental	O
protocol	O
of	O
this	O
study	O
was	O
approved	O
by	O
the	O
Ethics	O
Review	O
Committee	O
for	O
Animal	O
Experimentation	O
of	O
Juntendo	O
University	O
Faculty	O
of	O
Medicine	O
.	O

Experimental	O
Design	O

The	O
basal	O
mouse	B-OG
diet	O
included	O
the	O
original	O
formulation	O
(	O
AIN	O
-	O
93G	O
)	O
recommended	O
by	O
the	O
American	O
Institute	O
of	O
Nutrition	O
for	O
rodent	O
feeding	O
studies	O
[	O
26	O
].	O

Basal	O
diets	O
were	O
amended	O
to	O
yield	O
three	O
experimental	O
diets	O
containing	O
the	O
following	O
(	O
per	O
kg	O
):	O

low	O
Zn	O
diet	O
:	O
0	O
mg	O
Zn	O
;	O

normal	O
Zn	O
diet	O
:	O
67	O
mg	O
Zn	O
;	O
and	O

high	O
Zn	O
diet	O
:	O
1000	O
mg	O
Zn	O
.	O

All	O
diets	O
were	O
obtained	O
from	O
Oriental	O
Yeast	O
,	O
Tokyo	O
,	O
Japan	O
.	O

Female	O
gddY	O
mice	B-OG
at	O
7	O
weeks	O
were	O
randomly	O
divided	O
into	O
three	O
groups	O
:	O
low	O
,	O
normal	O
,	O
and	O
high	O
Zn	O
diet	O
groups	O
.	O

To	O
assess	O
the	O
exogenous	O
pathogen	O
-	O
mediated	O
immune	O
response	O
,	O
100	O
ng	O
LPS	O
(	O
055	O
:	O
B5	O
;	O
Sigma	O
,	O
USA	O
)	O
or	O
saline	O
as	O
a	O
vehicle	O
control	O
was	O
nasally	O
administered	O
to	O
mice	B-OG
from	O
each	O
group	O
four	O
times	O
every	O
12	O
h	O
before	O
sacrifice	O
.	O

A	O
histological	O
examination	O
was	O
performed	O
on	O
each	O
of	O
the	O
10	O
gddY	O
mice	B-OG
at	O
13	O
weeks	O
of	O
age	O
.	O

Blood	O
samples	O
were	O
obtained	O
from	O
the	O
buccal	O
vein	O
at	O
7	O
,	O
9	O
,	O
and	O
11	O
weeks	O
of	O
age	O
.	O

Serum	O
IgA	B-GP
,	O
IgG	B-GP
,	O
IgM	B-GP
,	O
and	O
IgA	B-GP
–	O
IgG	B-GP
IC	O
concentrations	O
were	O
measured	O
using	O
a	O
sandwich	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
kit	O
(	O
Bethyl	O
Laboratories	O
).	O

Urinary	O
samples	O
were	O
obtained	O
once	O
a	O
week	O
from	O
7	O
weeks	O
of	O
age	O
and	O
stored	O
at	O
−	O
80	O
°	O
C	O
until	O
analysis	O
.	O

Urinary	O
albumin	B-GP
and	O
creatinine	O
levels	O
were	O
measured	O
by	O
immunoassay	O
(	O
DCA	O
2000	O
system	O
;	O
Siemens	O
Healthcare	O
Diagnostics	O
,	O
Tokyo	O
,	O
Japan	O
)	O
[	O
25	O
].	O

Immunofluorescence	O

Kidneys	O
were	O
obtained	O
after	O
perfusion	O
with	O
normal	O
saline	O
.	O

Renal	O
specimens	O
were	O
mounted	O
in	O
an	O
optimal	O
cutting	O
temperature	O
(	O
OCT	O
)	O
compound	O
(	O
Sakura	O
Finetek	O
,	O
Tokyo	O
,	O
Japan	O
)	O
and	O
stored	O
at	O
−	O
80	O
°	O
C	O
.	O

Specimens	O
embedded	O
in	O
the	O
OCT	O
compound	O
were	O
cut	O
into	O
3	O
-	O
µm	O
sections	O
and	O
fixed	O
with	O
acetone	O
at	O
−	O
20	O
°	O
C	O
for	O
5	O
min	O
.	O

IgA	B-GP
and	O
IgG	B-GP
were	O
stained	O
by	O
immunofluorescent	O
staining	O
.	O

In	O
brief	O
,	O
the	O
sections	O
were	O
washed	O
with	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
),	O
blocked	O
with	O
a	O
blocking	O
agent	O
(	O
DS	O
Pharma	O
Biomedical	O
,	O
Osaka	O
,	O
Japan	O
)	O
at	O
room	O
temperature	O
for	O
30	O
min	O
,	O
and	O
incubated	O
with	O
DyLight	O
488	O
-	O
conjugated	O
goat	B-OG
anti	O
-	O
murine	O
IgA	B-GP
(	O
Bethyl	O
laboratories	O
,	O
Texas	O
,	O
USA	O
)	O
and	O
Alexa	O
555	O
-	O
conjugated	O
goat	B-OG
anti	O
-	O
murine	O
IgG	B-GP
(	O
Invitrogen	O
AG	O
,	O
Basel	O
,	O
Switzerland	O
)	O
antibodies	B-GP
at	O
room	O
temperature	O
for	O
120	O
min	O
.	O

After	O
three	O
washing	O
with	O
PBS	O
,	O
the	O
slides	O
were	O
mounted	O
with	O
a	O
mounting	O
medium	O
(	O
Dako	O
,	O
Tokyo	O
,	O
Japan	O
).	O

Samples	O
were	O
analyzed	O
and	O
imaged	O
using	O
confocal	O
laser	O
microscopy	O
(	O
Olympus	O
Corporation	O
,	O
Tokyo	O
,	O
Japan	O
).	O

For	O
the	O
semi	O
-	O
quantitative	O
analysis	O
of	O
the	O
glomerular	O
deposition	O
of	O
IgA	B-GP
or	O
IgG	B-GP
,	O
more	O
than	O
10	O
glomeruli	O
/	O
cross	O
section	O
were	O
observed	O
and	O
the	O
following	O
scores	O
were	O
assigned	O
:	O
1	O
point	O
,	O
no	O
glomerular	O
deposition	O
;	O
2	O
points	O
,	O
trivial	O
glomerular	O
deposition	O
;	O
3	O
points	O
,	O
mild	O
glomerular	O
deposition	O
;	O
4	O
points	O
,	O
moderate	O
glomerular	O
deposition	O
;	O
5	O
points	O
,	O
severe	O
glomerular	O
deposition	O
.	O

The	O
deposition	O
score	O
was	O
calculated	O
as	O
follows	O
:	O

Culture	O
of	O
Spleen	O
Cells	O

The	O
spleen	O
was	O
enucleated	O
under	O
aseptic	O
conditions	O
.	O

Spleen	O
cell	O
suspensions	O
were	O
prepared	O
by	O
compression	O
with	O
the	O
handle	O
of	O
a	O
syringe	O
in	O
a	O
Roswell	O
Park	O
Memorial	O
Institute	O
(	O
RPMI	O
)	O
1640	O
medium	O
,	O
followed	O
by	O
passage	O
through	O
a	O
100	O
-	O
µm	O
nylon	O
mesh	O
.	O

Red	O
blood	O
cells	O
were	O
removed	O
by	O
incubation	O
with	O
a	O
Red	O
Blood	O
Cell	O
Lysing	O
Buffer	O
(	O
R7757	O
;	O
Sigma	O
,	O
USA	O
)	O
at	O
room	O
temperature	O
for	O
1	O
min	O
,	O
followed	O
by	O
washing	O
in	O
a	O
RPMI	O
-	O
1640	O
medium	O
[	O
27	O
].	O

B	O
cells	O
,	O
T	O
cells	O
,	O
and	O
DCs	O
were	O
isolated	O
from	O
the	O
spleens	O
of	O
gddY	O
mice	B-OG
using	O
CD19	B-GP
MicroBeads	O
,	O
a	O
Pan	O
T	O
Cell	O
Isolation	O
Kit	O
,	O
and	O
Pan	O
DC	O
MicroBeads	O
(	O
MACS	O
;	O
Milteny	O
Biotec	O
,	O
Bergisch	O
Gladbach	O
,	O
Germany	O
)	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instructions	O
.	O

We	O
used	O
N	O
,	O
N	O
,	O
N	O
′,	O
N	O
′-	O
tetrakis	O
(	O
2	O
-	O
pyridylmethyl	O
)	O
ethylenediamine	O
(	O
TPEN	O
)	O
[	O
22	O
],	O
a	O
Zn	O
chelator	O
,	O
to	O
create	O
low	O
Zn	O
conditions	O
,	O
and	O
ZnSO4	O
with	O
pyrithione	O
to	O
create	O
high	O
Zn	O
conditions	O
[	O
22	O
].	O

LPS	O
(	O
055	O
:	O
B5	O
)	O
and	O
TPEN	O
,	O
2	O
,	O
2	O
′-	O
dithiodipyridine	O
(	O
D	O
-	O
5767	O
)	O
were	O
obtained	O
from	O
Sigma	O
.	O

Pyrithione	O
(	O
2	O
-	O
mercaptopyridine	O
N	O
-	O
oxide	O
;	O
P	O
-	O
24193	O
)	O
was	O
obtained	O
from	O
Invitrogen	O
.	O

An	O
RPMI	O
1640	O
medium	O
with	O
5	O
µM	O
TPEN	O
was	O
used	O
for	O
the	O
spleen	O
cell	O
culture	O
under	O
low	O
Zn	O
conditions	O
[	O
22	O
].	O

An	O
RPMI	O
1640	O
medium	O
with	O
5	O
µM	O
ZnSO4	O
and	O
3	O
µM	O
pyrithione	O
was	O
used	O
for	O
spleen	O
cell	O
culture	O
under	O
high	O
Zn	O
conditions	O
[	O
22	O
].	O

IgA	B-GP
production	O
by	O
individual	O
combinations	O
of	O
spleen	O
cells	O
was	O
measured	O
by	O
ELISA	O
after	O
48	O
h	O
incubation	O
.	O

To	O
evaluate	O
the	O
viability	O
of	O
B	O
cells	O
in	O
each	O
Zn	O
condition	O
,	O
we	O
cultured	O
splenic	O
B	O
cells	O
with	O
anti	O
-	O
CD40	B-GP
antibody	B-GP
(	O
553721	O
;	O
BD	O
Pharmingen	O
,	O
Tokyo	O
,	O
Japan	O
)	O
and	O
anti	O
-	O
IgM	B-GP
antibody	B-GP
(	O
115	O
-	O
006	O
-	O
020	O
;	O
Jackson	O
ImmunoResearch	O
Laboratories	O
,	O
Pennsylvania	O
,	O
USA	O
)	O
and	O
then	O
used	O
the	O
Cell	O
Counting	O
Kit	O
-	O
8	O
(	O
Dojindo	O
Laboratories	O
,	O
Tokyo	O
,	O
Japan	O
)	O
to	O
quantify	O
the	O
cells	O
.	O

Real	O
-	O
time	O
Reverse	O
Transcription	O
Polymerase	O
Chain	O
Reaction	O

RNA	O
from	O
spleen	O
cells	O
was	O
purified	O
with	O
an	O
RNeasy	O
Mini	O
Kit	O
(	O
74106	O
;	O
Qiagen	O
,	O
USA	O
)	O
after	O
Zn	O
conditioning	O
or	O
LPS	O
stimulation	O
.	O

A	O
SYBR	O
Green	O
PCR	O
Master	O
Mix	O
(	O
Applied	O
Biosystems	O
)	O
and	O
a	O
7500	O
Real	O
-	O
Time	O
PCR	O
System	O
(	O
Applied	O
Biosystems	O
)	O
were	O
used	O
for	O
the	O
quantitative	O
polymerase	O
chain	O
reaction	O
.	O

Transcript	O
levels	O
were	O
normalized	O
to	O
those	O
of	O
the	O
glyceraldehyde	B-GP
-	I-GP
3	I-GP
-	I-GP
phosphate	I-GP
dehydrogenase	I-GP
(	O
Gapdh	B-GP
)	O
gene	O
.	O

The	O
primer	O
sequences	O
used	O
were	O
as	O
follows	O
:	O
mouse	B-OG
TLR4	B-GP
,	O
TGGCACTGTTCTTCTCCTGCCT	O
and	O
GGAATGTCATCAGGGACTTTGCTGA	O
;	O
mouse	B-OG
TLR9	B-GP
,	O
TCTCCCAACATGGTTCTCCGTCG	O
and	O
TGCAGTCCAGGCCATGA	O
;	O
mouse	B-OG
MyD88	B-GP
,	O
GCACCTGTGTCTGGTCCATT	O
and	O
CTGTTGGACACCTGGAGACA	O
;	O
mouse	B-OG
TRIF	B-GP
,	O
TCTCTCCTCCTCCTCCAGCA	O
and	O
CGTCCCCTGCTGCAAAGAT	O
;	O
mouse	B-OG
interferon	B-GP
-	I-GP
β	I-GP
,	O
GTCCTCAACTGCTCTCCACT	O
and	O
CCAGGCGTAGCTGTTGTACT	O
;	O
and	O
mouse	B-OG
GAPDH	B-GP
,	O
CATTGTGGAAGGGCTCATGA	O
and	O
TCTTCTGGGTGGCAGTGATG	O
.	O

Statistical	O
Analysis	O

The	O
correlation	O
between	O
different	O
parameters	O
was	O
analyzed	O
using	O
analysis	O
of	O
variance	O
.	O

Data	O
are	O
expressed	O
as	O
the	O
mean	O
±	O
standard	O
deviation	O
or	O
median	O
values	O
.	O
p	O
values	O
<	O
0	O
.	O
05	O
were	O
considered	O
statistically	O
significant	O
.	O

All	O
statistical	O
analyses	O
were	O
performed	O
using	O
GraphPad	O
Prism	O
version	O
6	O
.	O
0	O
for	O
Windows	O
(	O
GraphPad	O
Software	O
,	O
San	O
Diego	O
,	O
CA	O
).	O

Results	O

Effect	O
of	O
Dietary	O
Zinc	O
in	O
the	O
IgAN	B-DS
Model	O
Mice	B-OG

We	O
divided	O
IgAN	B-DS
-	O
prone	O
gddY	O
mice	B-OG
into	O
three	O
dietary	O
groups	O
(	O
low	O
,	O
normal	O
,	O
and	O
high	O
Zn	O
diet	O
groups	O
)	O
and	O
assessed	O
IgAN	B-DS
progression	O
.	O

Serum	O
Zn	O
concentrations	O
significantly	O
differed	O
between	O
the	O
groups	O
from	O
the	O
fourth	O
week	O
after	O
dietary	O
intervention	O
(	O
Figure	O
1A	O
).	O

As	O
expected	O
,	O
body	O
weight	O
gain	O
was	O
suppressed	O
in	O
the	O
low	O
Zn	O
diet	O
group	O
because	O
of	O
growth	O
retardation	O
caused	O
by	O
the	O
Zn	B-DS
deficiency	I-DS
(	O
Figure	O
1B	O
).	O

Symptoms	O
such	O
as	O
diarrhea	O
were	O
not	O
caused	O
by	O
the	O
high	O
Zn	O
diet	O
.	O

Liver	B-DS
dysfunction	I-DS
was	O
not	O
observed	O
in	O
any	O
dietary	O
group	O
at	O
the	O
6th	O
week	O
.	O

To	O
avoid	O
various	O
redundant	O
negative	O
effects	O
of	O
a	O
long	O
-	O
term	O
Zn	B-DS
deficiency	I-DS
,	O
such	O
as	O
growth	O
retardation	O
or	O
severe	O
immunodeficiency	B-DS
,	O
we	O
evaluated	O
IgAN	B-DS
activity	O
in	O
the	O
sixth	O
week	O
after	O
intervention	O
.	O

Physiological	O
effect	O
of	O
dietary	O
zinc	O
intervention	O
.	O

(	O
A	O
)	O
Changes	O
in	O
serum	O
zinc	O
(	O
Zn	O
)	O
concentrations	O
.	O

Serum	O
Zn	O
concentrations	O
were	O
significantly	O
different	O
in	O
each	O
group	O
from	O
the	O
fourth	O
week	O
after	O
dietary	O
intervention	O
.	O

(	O
B	O
)	O
Changes	O
in	O
body	O
weights	O
.	O

Significant	O
body	O
weight	O
gain	O
was	O
suppressed	O
in	O
the	O
low	O
Zn	O
diet	O
group	O
.	O
*	O
p	O
<	O
0	O
.	O
05	O
;	O
***	O
p	O
<	O
0	O
.	O
001	O
.	O

Dietary	O
Zinc	O
Affects	O
the	O
Severity	O
of	O
Murine	O
IgAN	B-DS

The	O
number	O
of	O
splenic	O
B	O
cells	O
was	O
not	O
different	O
among	O
each	O
group	O
.	O

However	O
,	O
the	O
serum	O
concentrations	O
of	O
IgG	B-GP
,	O
IgA	B-GP
,	O
IgM	B-GP
,	O
and	O
IgA	B-GP
–	O
IgG	B-GP
ICs	O
in	O
the	O
low	O
and	O
normal	O
Zn	O
diet	O
groups	O
increased	O
during	O
the	O
course	O
of	O
the	O
disease	O
.	O

On	O
the	O
other	O
hand	O
,	O
a	O
significant	O
suppression	O
of	O
serum	O
IgA	B-GP
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
IgA	B-GP
–	O
IgG	B-GP
ICs	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
was	O
observed	O
in	O
the	O
high	O
Zn	O
diet	O
group	O
in	O
the	O
sixth	O
week	O
(	O
Figure	O
2	O
).	O

Serum	O
concentration	O
of	O
immunoglobulins	B-GP
for	O
each	O
dietary	O
zinc	O
condition	O
.	O

Dietary	O
zinc	O
intervention	O
altered	O
the	O
serum	O
concentrations	O
of	O
IgA	B-GP
and	O
IgA	B-GP
–	O
IgG	B-GP
immune	O
complexes	O
but	O
not	O
of	O
IgG	B-GP
and	O
IgM	B-GP
.	O
*	O
p	O
<	O
0	O
.	O
05	O
.	O

Urinary	O
albumin	B-GP
levels	O
in	O
the	O
low	O
Zn	O
diet	O
group	O
were	O
significantly	O
higher	O
than	O
that	O
in	O
the	O
normal	O
and	O
high	O
Zn	O
diet	O
groups	O
(	O
vs	O
.	O
normal	O
Zn	O
diet	O
group	O
:	O
p	O
<	O
0	O
.	O
05	O
;	O
vs	O
.	O
high	O
Zn	O
diet	O
group	O
:	O
p	O
<	O
0	O
.	O
01	O
)	O
in	O
the	O
sixth	O
week	O
(	O
Figure	O
3	O
).	O

The	O
intensity	O
of	O
glomerular	O
IgA	B-GP
deposition	O
in	O
the	O
high	O
Zn	O
diet	O
group	O
in	O
the	O
sixth	O
week	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
the	O
other	O
groups	O
(	O
vs	O
.	O
normal	O
Zn	O
diet	O
group	O
:	O
p	O
<	O
0	O
.	O
01	O
;	O
vs	O
.	O
low	O
Zn	O
diet	O
group	O
:	O
p	O
<	O
0	O
.	O
01	O
).	O

In	O
contrast	O
,	O
the	O
low	O
Zn	O
diet	O
group	O
exhibited	O
significantly	O
higher	O
IgG	B-GP
deposition	O
in	O
the	O
glomeruli	O
than	O
the	O
other	O
groups	O
(	O
vs	O
.	O
normal	O
Zn	O
diet	O
group	O
:	O
p	O
<	O
0	O
.	O
05	O
;	O
vs	O
.	O
high	O
Zn	O
diet	O
group	O
:	O
p	O
<	O
0	O
.	O
05	O
;	O
Figure	O
4	O
).	O

Urinary	O
albumin	B-GP
levels	O
for	O
each	O
dietary	O
zinc	O
condition	O
.	O

Urinary	O
levels	O
of	O
albumin	B-GP
were	O
significantly	O
higher	O
in	O
the	O
low	O
zinc	O
(	O
Zn	O
)	O
diet	O
group	O
and	O
lower	O
in	O
the	O
high	O
Zn	O
diet	O
group	O
on	O
the	O
sixth	O
week	O
.	O
*	O
p	O
<	O
0	O
.	O
05	O
;	O
**	O
p	O
<	O
0	O
.	O
01	O
.	O

Intensity	O
of	O
mesangial	O
IgA	B-GP
and	O
IgG	B-GP
deposition	O
.	O

The	O
intensity	O
of	O
IgA	B-GP
and	O
IgG	B-GP
deposition	O
was	O
scored	O
on	O
a	O
1	O
–	O
5	O
scale	O
based	O
on	O
an	O
average	O
of	O
more	O
than	O
10	O
glomeruli	O
.	O

IgA	B-GP
deposition	O
was	O
significantly	O
attenuated	O
in	O
the	O
high	O
zinc	O
(	O
Zn	O
)	O
diet	O
group	O
.	O

IgG	B-GP
deposition	O
in	O
the	O
low	O
Zn	O
diet	O
group	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
the	O
normal	O
and	O
high	O
Zn	O
diet	O
groups	O
.	O
*	O
p	O
<	O
0	O
.	O
05	O
;	O
**	O
p	O
<	O
0	O
.	O
01	O
.	O

Toll	B-GP
-	I-GP
like	I-GP
Receptor	I-GP
4	I-GP
Stimulation	O
Accelerates	O
Murine	O
IgAN	B-DS
Progression	O

To	O
investigate	O
whether	O
dietary	O
Zn	O
levels	O
influenced	O
the	O
mucosal	O
TLR	B-GP
-	O
mediated	O
aggravation	O
of	O
IgAN	B-DS
,	O
we	O
performed	O
nasal	O
challenges	O
with	O
CpG	O
DNA	O
and	O
LPS	O
in	O
each	O
dietary	O
group	O
.	O

The	O
effect	O
of	O
the	O
nasal	O
challenge	O
with	O
CpG	O
DNA	O
against	O
serum	O
immunoglobulins	B-GP
(	O
IgG	B-GP
,	O
IgA	B-GP
,	O
IgM	B-GP
,	O
and	O
IgA	B-GP
–	O
IgG	B-GP
ICs	O
)	O
and	O
urinary	O
albumin	B-GP
were	O
not	O
different	O
in	O
each	O
dietary	O
group	O
(	O
data	O
not	O
shown	O
).	O

Although	O
all	O
mice	B-OG
in	O
each	O
dietary	O
group	O
showed	O
an	O
aggravation	O
of	O
IgAN	B-DS
after	O
nasal	O
LPS	O
stimulation	O
,	O
increased	O
albuminuria	O
was	O
more	O
pronounced	O
in	O
the	O
low	O
Zn	O
diet	O
group	O
(	O
p	O
<	O
0	O
.	O
05	O
),	O
with	O
a	O
greater	O
increase	O
in	O
serum	O
concentrations	O
of	O
IgA	B-GP
(	O
p	O
<	O
0	O
.	O
07	O
)	O
and	O
IgA	B-GP
–	O
IgG	B-GP
ICs	O
(	O
p	O
<	O
0	O
.	O
05	O
;	O
Figure	O
5	O
).	O

In	O
contrast	O
,	O
the	O
changes	O
in	O
the	O
serum	O
concentrations	O
of	O
IgA	B-GP
and	O
IgA	B-GP
–	O
IgG	B-GP
ICs	O
after	O
LPS	O
stimulation	O
was	O
clearly	O
suppressed	O
in	O
the	O
high	O
Zn	O
diet	O
group	O
.	O

These	O
results	O
suggest	O
that	O
dietary	O
Zn	O
levels	O
influence	O
the	O
TLR4	B-GP
-	O
mediated	O
progression	O
of	O
murine	O
IgAN	B-DS
.	O

Reactivity	O
against	O
lipopolysaccharide	O
.	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
was	O
nasally	O
administered	O
to	O
some	O
mice	B-OG
in	O
each	O
dietary	O
group	O
,	O
while	O
others	O
received	O
saline	O
as	O
a	O
vehicle	O
control	O
;	O
samples	O
were	O
collected	O
during	O
the	O
sixth	O
week	O
.	O

We	O
calculated	O
the	O
ratio	O
(	O
sixth	O
:	O
fourth	O
week	O
)	O
of	O
each	O
parameter	O
.	O

Although	O
ACR	O
in	O
all	O
groups	O
increased	O
after	O
LPS	O
stimulation	O
,	O
the	O
elevation	O
in	O
the	O
low	O
zinc	O
(	O
Zn	O
)	O
diet	O
group	O
was	O
very	O
high	O
.	O

Serum	O
concentrations	O
of	O
IgA	B-GP
and	O
IgA	B-GP
–	O
IgG	B-GP
immune	O
complexes	O
(	O
ICs	O
)	O
in	O
the	O
low	O
and	O
normal	O
Zn	O
diet	O
groups	O
tended	O
to	O
be	O
higher	O
after	O
LPS	O
stimulation	O
.	O

However	O
,	O
the	O
high	O
Zn	O
diet	O
group	O
maintained	O
low	O
concentrations	O
of	O
serum	O
IgA	B-GP
and	O
IgA	B-GP
–	O
IgG	B-GP
ICs	O
despite	O
LPS	O
stimulation	O
.	O
*	O
p	O
<	O
0	O
.	O
05	O
.	O

Zinc	O
Regulation	O
Affects	O
IgA	B-GP
Production	O
by	O
Spleen	O
Cells	O

To	O
further	O
assess	O
the	O
association	O
between	O
dietary	O
Zn	O
levels	O
and	O
IgA	B-GP
production	O
,	O
we	O
examined	O
IgA	B-GP
production	O
by	O
spleen	O
cells	O
for	O
each	O
Zn	O
level	O
.	O

In	O
the	O
absence	O
of	O
LPS	O
,	O
IgA	B-GP
production	O
by	O
spleen	O
cells	O
in	O
low	O
Zn	O
conditions	O
was	O
significantly	O
higher	O
than	O
those	O
under	O
normal	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
high	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
Zn	O
conditions	O
(	O
Figure	O
6A	O
).	O

Furthermore	O
,	O
these	O
different	O
levels	O
of	O
IgA	B-GP
production	O
in	O
each	O
Zn	O
condition	O
were	O
independent	O
of	O
the	O
viability	O
of	O
B	O
cells	O
(	O
Figure	O
6B	O
).	O

Under	O
normal	O
and	O
low	O
Zn	O
conditions	O
,	O
IgA	B-GP
production	O
tended	O
to	O
be	O
higher	O
in	O
the	O
presence	O
of	O
LPS	O
.	O

However	O
,	O
under	O
high	O
Zn	O
conditions	O
,	O
serum	O
IgA	B-GP
concentration	O
remained	O
at	O
a	O
low	O
level	O
despite	O
the	O
presence	O
of	O
LPS	O
(	O
Figure	O
6C	O
).	O

IgA	B-GP
production	O
by	O
whole	O
spleen	O
cells	O
for	O
each	O
zinc	O
condition	O
.	O

(	O
A	O
)	O
Production	O
of	O
IgA	B-GP
was	O
significantly	O
higher	O
in	O
the	O
low	O
zinc	O
(	O
Zn	O
)	O
diet	O
group	O
and	O
lower	O
in	O
the	O
high	O
Zn	O
diet	O
group	O
.	O

(	O
B	O
)	O
The	O
viability	O
of	O
splenic	O
B	O
cells	O
in	O
each	O
Zn	O
condition	O
was	O
not	O
significantly	O
different	O
.	O

(	O
C	O
)	O
Reactivity	O
against	O
lipopolysaccharide	O
(	O
LPS	O
)	O
in	O
each	O
Zn	O
condition	O
.	O

In	O
the	O
normal	O
and	O
low	O
Zn	O
diet	O
groups	O
,	O
IgA	B-GP
production	O
tended	O
to	O
be	O
higher	O
in	O
the	O
presence	O
of	O
LPS	O
.	O

However	O
,	O
in	O
the	O
high	O
Zn	O
diet	O
group	O
,	O
serum	O
IgA	B-GP
concentration	O
remained	O
at	O
a	O
low	O
level	O
despite	O
of	O
the	O
presence	O
of	O
LPS	O
.	O
*	O
p	O
<	O
0	O
.	O
05	O
;	O
***	O
p	O
<	O
0	O
.	O
001	O
.	O

B	O
cells	O
,	O
T	O
cells	O
,	O
and	O
DCs	O
were	O
isolated	O
from	O
spleen	O
cells	O
to	O
further	O
investigate	O
the	O
influence	O
of	O
Zn	O
on	O
each	O
cell	O
type	O
and	O
their	O
interactions	O
.	O

As	O
expected	O
,	O
IgA	B-GP
production	O
by	O
B	O
cells	O
increased	O
when	O
cocultured	O
with	O
T	O
cells	O
and	O
/	O
or	O
DCs	O
(	O
Figure	O
7A	O
).	O

Under	O
low	O
Zn	O
conditions	O
,	O
IgA	B-GP
production	O
was	O
significantly	O
increased	O
in	O
the	O
presence	O
of	O
DCs	O
,	O
suggesting	O
that	O
elevated	O
IgA	B-GP
production	O
under	O
low	O
Zn	O
conditions	O
is	O
mainly	O
mediated	O
by	O
B	O
cell	O
–	O
DC	O
interaction	O
(	O
Figure	O
7B	O
).	O

In	O
contrast	O
,	O
under	O
high	O
Zn	O
conditions	O
,	O
IgA	B-GP
production	O
was	O
suppressed	O
in	O
all	O
cell	O
combinations	O
(	O
Figure	O
7B	O
).	O

Similar	O
results	O
were	O
evident	O
when	O
we	O
cultured	O
untreated	O
B	O
cells	O
with	O
T	O
cells	O
and	O
/	O
or	O
DCs	O
from	O
low	O
Zn	O
conditions	O
(	O
Figure	O
7C	O
).	O

In	O
addition	O
,	O
LPS	O
significantly	O
enhanced	O
IgA	B-GP
production	O
when	O
cocultured	O
with	O
DCs	O
(	O
p	O
<	O
0	O
.	O
001	O
),	O
confirming	O
that	O
DCs	O
activated	O
by	O
LPS	O
directly	O
increase	O
IgA	B-GP
production	O
in	O
a	O
T	O
cell	O
-	O
independent	O
manner	O
(	O
Figure	O
7D	O
).	O

However	O
,	O
when	O
we	O
cocultured	O
B	O
cells	O
and	O
DCs	O
from	O
gddY	O
or	O
BALB	B-OG
/	I-OG
c	I-OG
mice	I-OG
,	O
a	O
combination	O
of	O
both	O
B	O
cells	O
and	O
DCs	O
from	O
gddY	O
mice	B-OG
showed	O
the	O
highest	O
levels	O
of	O
IgA	B-GP
production	O
(	O
Figure	O
7E	O
).	O

Briefly	O
,	O
the	O
production	O
of	O
nephritogenic	O
IgA	B-GP
by	O
gddY	O
mice	B-OG
is	O
due	O
to	O
a	O
functional	O
abnormality	O
of	O
both	O
B	O
cells	O
and	O
DCs	O
.	O

IgA	B-GP
production	O
by	O
various	O
spleen	O
cells	O
.	O

(	O
A	O
)	O
IgA	B-GP
production	O
by	O
B	O
cells	O
increased	O
when	O
cocultured	O
with	O
T	O
cells	O
and	O
/	O
or	O
dendritic	O
cells	O
(	O
DCs	O
).	O

(	O
B	O
)	O
Under	O
low	O
zinc	O
(	O
Zn	O
)	O
conditions	O
,	O
IgA	B-GP
production	O
was	O
significantly	O
increased	O
in	O
the	O
presence	O
of	O
DCs	O
.	O

Under	O
high	O
Zn	O
conditions	O
,	O
IgA	B-GP
production	O
by	O
all	O
cell	O
combinations	O
was	O
suppressed	O
.	O

(	O
C	O
)	O
Coculture	O
of	O
untreated	O
B	O
cells	O
with	O
low	O
Zn	O
-	O
treated	O
T	O
cells	O
and	O
/	O
or	O
DCs	O
.	O

IgA	B-GP
production	O
increased	O
in	O
the	O
presence	O
of	O
DCs	O
.	O

(	O
D	O
)	O
Coculture	O
of	O
B	O
cells	O
and	O
DCs	O
with	O
or	O
without	O
lipopolysaccharide	O
(	O
LPS	O
).	O

LPS	O
significantly	O
enhanced	O
IgA	B-GP
production	O
despite	O
the	O
absence	O
of	O
T	O
cells	O
.	O

(	O
E	O
)	O
Coculture	O
of	O
B	O
cells	O
and	O
DCs	O
from	O
gddY	O
or	O
BALB	B-OG
/	I-OG
c	I-OG
mice	I-OG
.	O

A	O
combination	O
of	O
both	O
B	O
cells	O
and	O
DCs	O
from	O
gddY	O
mice	B-OG
yielded	O
the	O
highest	O
production	O
of	O
IgA	B-GP
.	O
**	O
p	O
<	O
0	O
.	O
01	O
;	O
***	O
p	O
<	O
0	O
.	O
001	O
.	O

Expression	O
levels	O
of	O
TLR4	B-GP
and	O
TLR9	B-GP
in	O
DCs	O
for	O
each	O
Zn	O
level	O
were	O
checked	O
with	O
or	O
without	O
LPS	O
stimulation	O
.	O

The	O
expression	O
of	O
TLR9	B-GP
was	O
unaffected	O
by	O
Zn	O
or	O
LPS	O
stimulation	O
(	O
data	O
not	O
shown	O
).	O

In	O
contrast	O
,	O
the	O
expression	O
of	O
TLR4	B-GP
significantly	O
increased	O
under	O
LPS	O
stimulation	O
under	O
low	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
normal	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
Zn	O
conditions	O
.	O

However	O
,	O
TLR4	B-GP
expression	O
under	O
high	O
Zn	O
conditions	O
was	O
attenuated	O
,	O
even	O
in	O
the	O
presence	O
of	O
LPS	O
(	O
vs	O
.	O
normal	O
Zn	O
diet	O
group	O
:	O
p	O
<	O
0	O
.	O
05	O
;	O
vs	O
.	O
low	O
Zn	O
diet	O
group	O
:	O
p	O
<	O
0	O
.	O
05	O
;	O
Figure	O
8A	O
).	O

We	O
also	O
examined	O
the	O
expression	O
of	O
MyD88	B-GP
and	O
TIR	B-GP
-	I-GP
domain	I-GP
-	I-GP
containing	I-GP
adapter	I-GP
-	I-GP
inducing	I-GP
interferon	I-GP
-	I-GP
β	I-GP
(	O
TRIF	B-GP
),	O
which	O
are	O
key	O
signaling	O
molecules	O
of	O
TLR4	B-GP
.	O

Although	O
the	O
expression	O
of	O
MyD88	B-GP
was	O
unaffected	O
by	O
Zn	O
(	O
Figure	O
8B	O
),	O
the	O
expression	O
of	O
TRIF	B-GP
under	O
low	O
Zn	O
conditions	O
was	O
significantly	O
upregulated	O
(	O
vs	O
.	O
normal	O
Zn	O
diet	O
group	O
:	O
p	O
<	O
0	O
.	O
05	O
;	O
vs	O
.	O
high	O
Zn	O
diet	O
group	O
:	O
p	O
<	O
0	O
.	O
05	O
;	O
Figure	O
8C	O
).	O

To	O
confirm	O
the	O
functional	O
alteration	O
of	O
the	O
TLR4	B-GP
/	O
TRIF	B-GP
pathway	O
caused	O
by	O
Zn	O
,	O
we	O
examined	O
the	O
expression	O
of	O
interferon	B-GP
-	I-GP
β	I-GP
,	O
which	O
is	O
specifically	O
induced	O
by	O
the	O
activation	O
of	O
the	O
TRIF	B-GP
-	O
dependent	O
pathway	O
following	O
TLR4	B-GP
activation	O
[	O
28	O
],	O
[	O
29	O
].	O

The	O
expression	O
of	O
interferon	B-GP
-	I-GP
β	I-GP
was	O
higher	O
in	O
low	O
Zn	O
condition	O
and	O
lower	O
in	O
high	O
Zn	O
condition	O
.	O

(	O
Figure	O
8D	O
).	O

Expression	O
of	O
Toll	B-GP
-	I-GP
like	I-GP
receptor	I-GP
4	I-GP
,	O
MyD88	B-GP
,	O
TRIF	B-GP
,	O
and	O
interferon	B-GP
-	I-GP
β	I-GP
in	O
each	O
zinc	O
condition	O
.	O

(	O
A	O
)	O
Expression	O
of	O
Toll	B-GP
-	I-GP
like	I-GP
receptor	I-GP
4	I-GP
(	O
TLR4	B-GP
)	O
for	O
each	O
zinc	O
(	O
Zn	O
)	O
condition	O
with	O
/	O
without	O
lipopolysaccharide	O
(	O
LPS	O
).	O

Expression	O
of	O
TLR4	B-GP
was	O
significantly	O
increased	O
when	O
stimulated	O
by	O
LPS	O
under	O
low	O
and	O
normal	O
Zn	O
conditions	O
.	O

However	O
,	O
TLR4	B-GP
expression	O
under	O
high	O
Zn	O
conditions	O
was	O
low	O
despite	O
LPS	O
stimulation	O
.	O

(	O
B	O
)	O
Expression	O
of	O
MyD88	B-GP
at	O
each	O
Zn	O
condition	O
.	O

Expression	O
of	O
MyD88	B-GP
remained	O
constant	O
at	O
each	O
Zn	O
condition	O
.	O

(	O
C	O
)	O
Expression	O
of	O
TRIF	B-GP
for	O
each	O
Zn	O
condition	O
.	O

Expression	O
of	O
TRIF	B-GP
under	O
low	O
Zn	O
conditions	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
other	O
groups	O
.	O

(	O
D	O
)	O
Expression	O
of	O
interferon	B-GP
-	I-GP
β	I-GP
in	O
each	O
Zn	O
condition	O
.	O

Expression	O
of	O
interferon	B-GP
-	I-GP
β	I-GP
was	O
higher	O
in	O
low	O
Zn	O
condition	O
and	O
lower	O
in	O
high	O
Zn	O
condition	O
.	O
*	O
p	O
<	O
0	O
.	O
05	O
;	O
**	O
p	O
<	O
0	O
.	O
01	O
.	O

Discussion	O

Environmental	O
factors	O
are	O
considered	O
to	O
have	O
an	O
impact	O
on	O
susceptibility	O
to	O
IgAN	B-DS
.	O

Johnson	O
et	O
al	O
.	O
[	O
7	O
]	O
assessed	O
the	O
geographic	O
bias	O
in	O
the	O
prevalence	O
,	O
from	O
the	O
perspective	O
of	O
the	O
immunological	O
effects	O
of	O
exposure	O
to	O
exogenous	O
antigens	O
.	O

Moreover	O
,	O
diet	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
IgAN	B-DS
,	O
as	O
well	O
as	O
in	O
other	O
atopic	B-DS
diseases	I-DS
[	O
30	O
]	O
considered	O
to	O
be	O
associated	O
with	O
hygiene	O
.	O

As	O
dietary	O
intervention	O
is	O
easy	O
and	O
has	O
few	O
adverse	O
effects	O
,	O
clarifying	O
the	O
association	O
between	O
diet	O
and	O
such	O
diseases	O
through	O
dietary	O
intervention	O
may	O
represent	O
an	O
important	O
step	O
toward	O
new	O
potential	O
treatments	O
for	O
IgAN	B-DS
.	O

However	O
,	O
few	O
reports	O
,	O
except	O
for	O
a	O
small	O
number	O
on	O
fish	B-OG
oil	O
[	O
11	O
]	O
and	O
gluten	B-GP
[	O
5	O
],	O
discuss	O
the	O
connection	O
of	O
diet	O
and	O
renal	B-DS
diseases	I-DS
.	O

It	O
is	O
difficult	O
to	O
identify	O
one	O
key	O
factor	O
among	O
the	O
vast	O
number	O
of	O
nutritive	O
components	O
involved	O
in	O
diet	O
.	O

In	O
this	O
study	O
,	O
we	O
focused	O
on	O
the	O
immunological	O
functions	O
of	O
Zn	O
,	O
an	O
important	O
component	O
of	O
the	O
immune	O
system	O
,	O
and	O
investigated	O
the	O
relationship	O
between	O
dietary	O
Zn	O
levels	O
and	O
IgAN	B-DS
development	O
.	O

We	O
discovered	O
that	O
the	O
dietary	O
Zn	O
levels	O
are	O
critically	O
involved	O
in	O
the	O
immune	O
process	O
of	O
nephritogenic	O
IgA	B-GP
production	O
by	O
affecting	O
the	O
activity	O
of	O
DCs	O
,	O
especially	O
through	O
the	O
TLR4	B-GP
/	O
TRIF	B-GP
pathway	O
.	O

We	O
used	O
IgAN	B-DS
-	O
prone	O
gddY	O
mice	B-OG
,	O
which	O
exhibit	O
the	O
same	O
renal	O
phenotype	O
and	O
dysregulation	O
of	O
the	O
systemic	O
immune	O
system	O
as	O
patients	O
with	O
IgAN	B-DS
.	O

We	O
recently	O
demonstrated	O
that	O
the	O
renal	O
prognosis	O
of	O
gddY	O
mice	B-OG
may	O
be	O
linked	O
to	O
differences	O
in	O
sugar	O
content	O
or	O
the	O
O	O
-	O
glycosylation	O
acceptor	O
site	O
of	O
the	O
IgA	B-GP
hinge	O
region	O
[	O
25	O
].	O

These	O
findings	O
suggest	O
that	O
the	O
progression	O
of	O
this	O
murine	O
IgAN	B-DS
also	O
may	O
be	O
dependent	O
on	O
the	O
aberrantly	O
glycosylated	O
IgA	B-GP
,	O
similar	O
to	O
that	O
seen	O
in	O
human	B-OG
IgAN	B-DS
.	O

We	O
previously	O
reported	O
that	O
,	O
in	O
ddY	O
mice	B-OG
under	O
conventional	O
conditions	O
the	O
serum	O
concentrations	O
of	O
IgA	B-GP
,	O
but	O
not	O
those	O
of	O
IgG	B-GP
and	O
IgM	B-GP
,	O
were	O
significantly	O
elevated	O
relative	O
to	O
mice	B-OG
maintained	O
under	O
specific	O
pathogen	O
-	O
free	O
(	O
SPF	O
)	O
conditions	O
[	O
8	O
].	O

This	O
study	O
showed	O
that	O
Zn	O
supplementation	O
suppressed	O
urinary	O
albumin	B-GP
levels	O
in	O
association	O
with	O
a	O
decrease	O
in	O
the	O
serum	O
concentrations	O
of	O
IgA	B-GP
and	O
IgA	B-GP
–	O
IgG	B-GP
ICs	O
,	O
but	O
not	O
those	O
of	O
IgG	B-GP
and	O
IgM	B-GP
.	O

These	O
findings	O
led	O
us	O
to	O
conclude	O
that	O
Zn	O
-	O
mediated	O
mechanisms	O
are	O
specifically	O
involved	O
in	O
the	O
increased	O
nephritogenic	O
IgA	B-GP
production	O
in	O
response	O
to	O
mucosal	O
exogenous	O
antigens	O
.	O

In	O
fact	O
,	O
the	O
dietary	O
Zn	O
supplementation	O
reduced	O
mesangial	O
IgA	B-GP
deposition	O
,	O
in	O
association	O
with	O
decreasing	O
concentrations	O
of	O
IgA	B-GP
and	O
IgA	B-GP
–	O
IgG	B-GP
ICs	O
,	O
even	O
after	O
mucosal	O
LPS	O
stimulation	O
.	O

In	O
contrast	O
,	O
low	O
Zn	O
levels	O
worsened	O
the	O
course	O
of	O
the	O
disease	O
with	O
or	O
without	O
LPS	O
.	O

These	O
results	O
suggest	O
that	O
the	O
dietary	O
Zn	O
levels	O
influence	O
the	O
mucosal	O
immune	O
response	O
,	O
including	O
nephritogenic	O
IgA	B-GP
production	O
.	O

The	O
in	O
vitro	O
study	O
confirmed	O
the	O
in	O
vivo	O
results	O
:	O
IgA	B-GP
production	O
by	O
splenocytes	O
was	O
increased	O
at	O
low	O
Zn	O
levels	O
and	O
decreased	O
at	O
high	O
Zn	O
levels	O
.	O

Interestingly	O
,	O
the	O
influence	O
of	O
Zn	O
on	O
IgA	B-GP
production	O
was	O
abrogated	O
in	O
the	O
absence	O
of	O
DCs	O
.	O

To	O
avoid	O
a	O
direct	O
effect	O
of	O
Zn	O
on	O
B	O
cells	O
,	O
we	O
cocultured	O
untreated	O
B	O
cells	O
with	O
Zn	O
-	O
treated	O
T	O
cells	O
and	O
/	O
or	O
DCs	O
and	O
obtained	O
similar	O
results	O
.	O

These	O
findings	O
indicate	O
that	O
Zn	O
regulation	O
is	O
associated	O
with	O
an	O
immune	O
reaction	O
mediated	O
by	O
DCs	O
.	O

On	O
the	O
other	O
hand	O
,	O
DCs	O
from	O
gddY	O
mice	B-OG
played	O
a	O
critical	O
role	O
in	O
IgA	B-GP
production	O
.	O

The	O
concentration	O
of	O
IgA	B-GP
production	O
by	O
B	O
cells	O
was	O
higher	O
when	O
cocultured	O
with	O
DCs	O
,	O
irrespective	O
of	O
the	O
presence	O
of	O
T	O
cells	O
.	O

Similarly	O
,	O
in	O
a	O
T	O
cell	O
-	O
independent	O
manner	O
,	O
DCs	O
stimulated	O
by	O
LPS	O
directly	O
altered	O
the	O
IgA	B-GP
production	O
by	O
B	O
cells	O
(	O
Figure	O
7D	O
).	O

It	O
was	O
also	O
evident	O
that	O
DCs	O
from	O
gddY	O
mice	B-OG
were	O
capable	O
of	O
inducing	O
higher	O
levels	O
of	O
IgA	B-GP
production	O
by	O
B	O
cells	O
than	O
the	O
same	O
number	O
of	O
DCs	O
from	O
BALB	B-OG
/	I-OG
c	I-OG
mice	I-OG
,	O
even	O
when	O
cultured	O
under	O
the	O
same	O
conditions	O
(	O
Figure	O
7E	O
),	O
suggesting	O
that	O
DCs	O
from	O
gddY	O
mice	B-OG
have	O
an	O
increased	O
capacity	O
to	O
induce	O
IgA	B-GP
production	O
than	O
those	O
from	O
BALB	B-OG
/	I-OG
c	I-OG
mice	I-OG
.	O

Next	O
,	O
we	O
analyzed	O
the	O
effect	O
of	O
Zn	O
and	O
exogenous	O
antigens	O
on	O
DCs	O
.	O

We	O
previously	O
reported	O
that	O
the	O
activation	O
of	O
the	O
TLR9	B-GP
/	O
MyD88	B-GP
pathway	O
on	O
B	O
cells	O
or	O
DCs	O
is	O
a	O
critical	O
determinant	O
of	O
IgAN	B-DS
severity	O
[	O
8	O
],	O
[	O
31	O
].	O

However	O
,	O
this	O
study	O
revealed	O
that	O
Zn	O
affects	O
the	O
reactivity	O
of	O
TLR4	B-GP
,	O
but	O
not	O
that	O
of	O
TLR9	B-GP
.	O

Thus	O
,	O
we	O
assessed	O
the	O
expression	O
of	O
TLR4	B-GP
in	O
splenic	O
DCs	O
under	O
various	O
Zn	O
and	O
LPS	O
conditions	O
.	O

Although	O
LPS	O
stimulation	O
increased	O
TLR4	B-GP
expression	O
by	O
DCs	O
under	O
normal	O
and	O
low	O
Zn	O
conditions	O
,	O
there	O
was	O
little	O
change	O
in	O
TLR4	B-GP
expression	O
by	O
DCs	O
under	O
high	O
Zn	O
conditions	O
,	O
irrespective	O
of	O
LPS	O
stimulation	O
.	O

This	O
result	O
is	O
consistent	O
with	O
a	O
previous	O
report	O
demonstrating	O
that	O
Zn	O
homeostasis	O
is	O
involved	O
in	O
some	O
DC	O
maturation	O
events	O
and	O
affects	O
the	O
magnitude	O
of	O
immune	O
responses	O
via	O
the	O
activation	O
of	O
TLR4	B-GP
[	O
22	O
].	O

Each	O
TLR	B-GP
triggers	O
a	O
specific	O
biological	O
response	O
.	O

MyD88	B-GP
is	O
universally	O
used	O
by	O
all	O
TLRs	B-GP
except	O
TLR3	B-GP
,	O
and	O
induces	O
inflammatory	B-GP
cytokines	I-GP
.	O

In	O
contrast	O
,	O
TRIF	B-GP
is	O
used	O
by	O
TLR3	B-GP
and	O
TLR4	B-GP
only	O
.	O

TLR4	B-GP
is	O
therefore	O
the	O
only	O
TLR	B-GP
that	O
activates	O
both	O
the	O
MyD88	B-GP
and	O
TRIF	B-GP
signaling	O
pathways	O
[	O
29	O
].	O

We	O
investigated	O
the	O
expression	O
of	O
these	O
two	O
signaling	O
molecules	O
.	O

Although	O
MyD88	B-GP
expression	O
was	O
unaltered	O
at	O
each	O
Zn	O
level	O
,	O
TRIF	B-GP
expression	O
was	O
significantly	O
higher	O
at	O
low	O
Zn	O
levels	O
.	O

MyD88	B-GP
induces	O
inflammatory	O
responses	O
by	O
activating	O
NF	B-GP
-	I-GP
κB	I-GP
and	O
MAPK	B-GP
,	O
whereas	O
TRIF	B-GP
recruits	O
TRADD	B-GP
,	O
TRAF6	B-GP
,	O
and	O
TRAF3	B-GP
.	O

TRADD	B-GP
and	O
TRAF6	B-GP
also	O
lead	O
to	O
activation	O
of	O
MAPK	B-GP
and	O
NF	B-GP
-	I-GP
κB	I-GP
.	O

On	O
the	O
other	O
hand	O
,	O
TRAF3	B-GP
activates	O
some	O
kinases	B-GP
,	O
such	O
as	O
TBK1	B-GP
and	O
IKKi	B-GP
,	O
and	O
subsequently	O
,	O
IRF3	B-GP
,	O
which	O
is	O
a	O
key	O
transcriptional	B-GP
factor	I-GP
for	O
interferon	B-GP
-	I-GP
β	I-GP
[	O
29	O
].	O

Therefore	O
,	O
during	O
TLR4	B-GP
activation	O
,	O
interferon	B-GP
-	I-GP
β	I-GP
is	O
specifically	O
induced	O
by	O
the	O
TRIF	B-GP
signaling	O
pathway	O
and	O
not	O
by	O
the	O
MyD88	B-GP
signaling	O
pathway	O
.	O

The	O
present	O
study	O
showed	O
that	O
expression	O
levels	O
of	O
interferon	B-GP
-	I-GP
β	I-GP
and	O
TRIF	B-GP
were	O
both	O
enhanced	O
in	O
low	O
Zn	O
conditions	O
,	O
indicating	O
the	O
involvement	O
of	O
Zn	O
in	O
the	O
TRIF	B-GP
pathway	O
.	O

Furthermore	O
,	O
although	O
expression	O
levels	O
of	O
TRIF	B-GP
were	O
not	O
significantly	O
different	O
,	O
expression	O
levels	O
of	O
interferon	B-GP
-	I-GP
β	I-GP
in	O
high	O
Zn	O
conditions	O
were	O
lower	O
than	O
those	O
in	O
normal	O
Zn	O
conditions	O
.	O

These	O
data	O
suggest	O
that	O
a	O
high	O
Zn	O
condition	O
may	O
directly	O
attenuate	O
the	O
activation	O
of	O
the	O
downstream	O
TRIF	B-GP
signaling	O
pathway	O
rather	O
than	O
TRIF	B-GP
expression	O
itself	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
in	O
vivo	O
and	O
other	O
in	O
vitro	O
experiments	O
,	O
and	O
therefore	O
,	O
provide	O
further	O
support	O
for	O
the	O
Zn	O
effect	O
on	O
IgA	B-GP
production	O
via	O
the	O
TLR4	B-GP
/	O
TRIF	B-GP
pathway	O
.	O

In	O
summary	O
,	O
we	O
demonstrated	O
that	O
Zn	O
alters	O
nephritogenic	O
IgA	B-GP
production	O
and	O
,	O
thus	O
,	O
is	O
critically	O
involved	O
in	O
disease	O
activity	O
in	O
murine	O
IgAN	B-DS
.	O

These	O
findings	O
suggest	O
that	O
diet	O
,	O
as	O
a	O
major	O
environmental	O
factor	O
,	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
IgAN	B-DS
,	O
as	O
well	O
as	O
in	O
other	O
immune	B-DS
-	I-DS
related	I-DS
diseases	I-DS
.	O

Zn	O
modulates	O
IgA	B-GP
production	O
by	O
altering	O
the	O
activity	O
of	O
DCs	O
,	O
especially	O
via	O
TLR4	B-GP
/	O
TRIF	B-GP
.	O

In	O
other	O
words	O
,	O
dietary	O
Zn	O
levels	O
may	O
determine	O
the	O
susceptibility	O
to	O
environmental	O
factors	O
,	O
such	O
as	O
exogenous	O
antigens	O
.	O

As	O
a	O
recent	O
study	O
demonstrated	O
the	O
clinical	O
application	O
of	O
Zn	O
supplements	O
combined	O
with	O
other	O
supplementation	O
in	O
immune	B-DS
-	I-DS
related	I-DS
diseases	I-DS
,	O
including	O
asthma	B-DS
,	O
Zn	O
supplementation	O
represents	O
a	O
therapeutic	O
strategy	O
for	O
preventing	O
the	O
progression	O
or	O
aggravation	O
of	O
IgAN	B-DS
[	O
32	O
].	O

